Bayer’s foundation handed out its 2026 Science Awards on Tuesday, honoring five researchers — and for the first time, one of those prizes went to plant science. Sarah O’Connor took home the Otto Bayer Prize. It is a genuine accolade, but investors should file it under a separate heading from the company’s drug pipeline and its upcoming financial disclosure.
The distinction matters because three recent Bayer developments sit at three different stages of completion, and only one of them has a fixed date attached.
A first for plant research
According to the Bayer Foundation, this year marked the inaugural award in the plant sciences, putting the field itself in the spotlight alongside the individual laureates. O’Connor received the prize named after Otto Bayer.
That is news from the world of research funding. What actually moves the needle for Bayer’s economics are the concrete steps in its medicines business and the quarterly report now on the horizon. Scientific honors and operational announcements, in other words, deserve to be read on separate pages.
Two pharma items, two very different statuses
Roughly a week ago, the US Food and Drug Administration accepted Bayer’s application for Finerenon in chronic kidney disease without diabetes. Per the company, the filing leans on data from the Phase III FIND-CKD trial.
Acceptance is not approval. The procedural milestone concerns the application for that specific patient group and should not be mistaken for a green light already granted.
Should investors sell immediately? Or is it worth buying Bayer?
About two weeks ago, Bayer also unveiled a USD 2.2 billion investment in a new pharma production site in New Albany, Ohio, where it plans to create some 600 jobs. The first production area is slated to come online in 2031.
Here too, status is everything: Bayer has announced the project, not completed it. The planned output is a capital commitment, not a finished expansion. Taken together, the two disclosures open different fronts in the pharma business without carrying the same economic weight.
What the share price is — and isn’t — telling you
Media reports attributed yesterday’s support for the stock to both the strength of the pharmaceutical sector and the two company announcements, without naming a single clear trigger. Today’s gain of 1.9% fits that friendly picture but says nothing on its own about the earnings due next.
JPMorgan’s caution and the November date
JPMorgan kept Bayer at “Overweight” with a price target of EUR 61 about two weeks ago. Analyst Richard Vosser flagged that market expectations for the third quarter might be too high, pointing to a timing-related effect in the agriculture division. He simultaneously saw no major changes to full-year estimates — an assessment that explicitly separated a possible quarterly distortion from the broader annual view.
The next quarterly report is scheduled for November 3, 2026, with the accompanying earnings call set for 14:00 CET. That is when investors can check how Bayer frames its business performance and whether the caution voiced by JPMorgan holds up. Until then, the pharma headlines offer encouraging signposts for future development — but no substitute for operating results.
Ad
Bayer Stock: Buy or Sell?! New Bayer Analysis from October 15 delivers the answer:
The latest Bayer figures speak for themselves: Urgent action needed for Bayer investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from October 15.
Bayer: Buy or sell? Read more here...
